Reference health
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
32/32 checkable references clean · checked 2026-07-25
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 32 checked references that resolve
resolves10.15585/mmwr.mm6924e2
Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020
resolves10.1093/cid/ciaa1419
Risk Factors for Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization: COVID-19–Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System
resolves10.15585/mmwr.mm7010e4
Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020
resolves10.1080/07853890.2021.1957998
Changes in COVID-19 vaccination receipt and intention to vaccinate by socioeconomic characteristics and geographic area, United States, January 6 – March 29, 2021
resolves10.1056/EVIDoa2100044
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
resolves10.1056/NEJMoa2107934
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
resolves10.1093/cid/ciab494
Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression
resolves10.1128/AAC.00766-18
Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses
resolves10.1038/s41564-020-00835-2
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
resolves10.1126/scitranslmed.abb5883
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
resolves10.1038/s41586-021-03312-w
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
resolves10.1093/infdis/jiab361
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
resolves10.1128/JVI.01348-19
Small-Molecule Antiviral β-
<scp>d</scp>
-
<i>N</i>
<sup>4</sup>
-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
resolves10.1128/JVI.01965-17
β-
<scp>d</scp>
-
<i>N</i>
<sup>4</sup>
-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome
resolves10.1128/AAC.02428-20
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
resolves10.1093/jac/dkab318
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
resolves10.1002/sim.4780091207
Group sequential designs using a family of type I error probability spending functions
resolves10.15585/mmwr.mm7037a7
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
resolves10.1056/EVIDoa2100043
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
resolves10.15585/mmwr.mm6930e1
Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020
resolves10.15585/mmwr.mm7034e2
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
resolves10.15585/mmwr.mm7037e3
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021
resolves10.1001/jama.2021.0202
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
resolves10.1093/ofid/ofab268
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants
resolves10.1093/ofid/ofab313
Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City
The 6 references without a DOI — listed, not checked
no DOI — not checkedWHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization 2021 (https://covid19.who.int).
no DOI — not checkedGrobler J Strizki J Murgolo N et al. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies. In: Proceedings and abstracts of IDWeek 2021 September 29–October 3 2021. Arlington VA: Infectious Diseases Society of America 2021.
no DOI — not checkedChawla A Cao Y Stone J et al. Model-based dose selection for the phase 3 evaluation of molnupiravir (MOV) in the treatment of COVID-19 in adults. In: Proceedings and abstracts of the 31st Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases July 9–12 2021. Basel Switzerland: European Society of Clinical Microbiology and Infectious Diseases 2021.
no DOI — not checkedCOVID-19: developing drugs and biological products for treatment or prevention: guidance for industry. Silver Spring MD: Food and Drug Administration May 2020 (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention).
no DOI — not checkedWHO COVID-19 case definitions. Geneva: World Health Organization December 16 2020 (https://apps.who.int/iris/rest/bitstreams/1322790/retrieve).
no DOI — not checkedHorby PW Mafham M Peto L et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled open-label platform trial. June 16 2021 (https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1). preprint.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-25 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1056/nejmoa2116044"><img src="https://citestamp.com/citestamped/10.1056/nejmoa2116044/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1056/nejmoa2116044)